Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Survival and CNS Relapse in Patients with CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study in Japan

Blood (2023) 142 (Supplement 1): 1762.

https://doi.org/10.1182/blood-2023-174647

Published: 2023

Journal Articles

Prospective Study of the Usefulness of Liquid Biopsy in Patients with Unknown Fever Suspected of Malignant Lymphoma

Blood (2022) 140 (Supplement 1): 6690–6692.

https://doi.org/10.1182/blood-2022-157438

Published: 2022

Journal Articles

CD20 Protein Immunohistochemistry-Positive/Flow Cytometry-Negative Diffuse Large B-Cell Lymphoma—Analyses of the Molecular Mechanisms and Rituximab Effectiveness

Takashi Tokunaga, MD, Akihiro Tomita, MD, PhD, Junji Hiraga, MD, PhD, Takumi Sugimoto, MD, PhD, Kazuyuki Shimada, MD, PhD, Keiki Sugimoto, Tomohiro Kinoshita, MD, PhD, Tomoki Naoe, MD, PhD.

Blood (2011) 118 (21): 2659.

https://doi.org/10.1182/blood.V118.21.2659.2659

Published: 2011

Journal Articles

Clinical Significance of Genetic Mutations of CD79B , CARD11 , MYD88 , and EZH2 Genes in Diffuse Large B-Cell Lymphoma Patients

Chisako Iriyama, MD, Akihiro Tomita, MD, PhD, Takashi Tokunaga, MD, Keisuke Sugiyama, PharmD, Junji Hiraga, MD, PhD, Tomohiro Kinoshita, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2011) 118 (21): 2633.

https://doi.org/10.1182/blood.V118.21.2633.2633

Published: 2011

Journal Articles

Retention of Slow-Cycling CD34 + cells During Imatinib Treatment and Rapid Decline After 2nd ABL-TKI Treatment in Ph + Leukemia Cells

Yosuke Minami, MD, PhD, Akihiro Abe, Miho Minami, Yachiyo Kuwatsuka, Nobuaki Fukushima, Kunio Kitamura, Junji Hiraga, MD, PhD, Kazuhito Yamamoto, MD, PhD, Catriona Jamieson, Tomoki Naoe, MD, PhD

Blood (2011) 118 (21): 641.

https://doi.org/10.1182/blood.V118.21.641.641

Published: 2011

Journal Articles

CD20-Negative Phenotypic Change In B-Cell Lymphoma Cells After Using Rituximab: Possibility of a Particular Clinicopathologic Phenomenon Post-Rituximab Extranodal CD20-Negative Lymphoma

Akihiro Tomita, MD, PhD, Takashi Tokunaga, MD, Chisako Iriyama, MD, Kazuyuki Shimada, MD, PhD, Junji Hiraga, MD, PhD, Takumi Sugimoto, MD, PhD, Hitoshi Kiyoi, MD, PhD, Shigeo Nakamura, MD, PhD, Tomohiro Kinoshita, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2010) 116 (21): 2874.

https://doi.org/10.1182/blood.V116.21.2874.2874

Published: 2010

Journal Articles

Rapid Reduction of Chronic Myeloid Leukemia Stem Cells After Treatment with Second-Generation BCR-ABL Kinase Inhibitors, Dasatinib and Nilotinib

Yosuke Minami, MD, PhD, Akihiro Abe, Yuka Nomura, Miho Minami, Yachiyo Kuwatsuka, Kunio Kitamura, Junji Hiraga, Shinichi Mizuno, Kazuhito Yamamoto, Tomohiro Kajiguchi, Masashi Sawa, Yuichiro Inagaki, Toshiya Yokozawa, Etsuko Aoki, Kazutaka Ozeki, Keisuke Watanabe, Koichi Miyamura, Hitoshi Kiyoi, Tomoki Naoe

Blood (2010) 116 (21): 4457.

https://doi.org/10.1182/blood.V116.21.4457.4457

Published: 2010

Journal Articles

Discrepancy of CD20 Protein Expression In IHC and FCM Analyses In Primary B-Cell Lymphoma: Relationship Between FCM-Negative Phenotype and Rituximab Binding with Lymphoma Cells

Takashi Tokunaga, MD, Akihiro Tomita, MD, PhD, Kazuyuki Shimada, MD, PhD, Junji Hiraga, MD, PhD, Takumi Sugimoto, MD, PhD, Naoe Goto, MD, PhD, Tsuyoshi Takami, MD, PhD, Tomohiro Kinoshita, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2010) 116 (21): 5087.

https://doi.org/10.1182/blood.V116.21.5087.5087

Published: 2010

Journal Articles

MS4A1 (CD20) Gene Expression Is Down-Regulated by Recruiting the Histone Deacetylase Protein Complex to the Promoter in the CD20-Negative B-Lymphoma Cells After Treatment with Rituximab.

Takumi Sugimoto, MD, Akihiro Tomita, MD, Ph.D., Junji Hiraga, MD, Ph.D., Kazuyuki Shimada, MD, Ph.D., Hitoshi Kiyoi, MD, Ph.D., Tomohiro Kinoshita, MD, Ph.D., Tomoki Naoe, MD, Ph.D.

Blood (2009) 114 (22): 1286.

https://doi.org/10.1182/blood.V114.22.1286.1286

Published: 2009

Journal Articles

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance

Junji Hiraga, Akihiro Tomita, Takumi Sugimoto, Kazuyuki Shimada, Masafumi Ito, Shigeo Nakamura, Hitoshi Kiyoi, Tomohiro Kinoshita, Tomoki Naoe

Blood (2009) 113 (20): 4885–4893.

https://doi.org/10.1182/blood-2008-08-175208

Published: 2009

Includes: Supplemental data

Journal Articles

Relationship Between Post-Translational Modification of CD20 Protein and the Responsiveness to Rituximab Treatment

Takumi Sugimoto, MD, Akihiro Tomita, MD, Kazuyuki Shimada, MD, Junji Hiraga, MD, Hitoshi Kiyoi, MD, Tomohiro Kinoshita, MD, Tomoki Naoe, MD

Blood (2008) 112 (11): 2667.

https://doi.org/10.1182/blood.V112.11.2667.2667

Published: 2008

Journal Articles

Epigenetic Regulation of CD20 Protein Expression in B-Cell Lymphoma Cells after Rituximab-Containing Chemotherapy.

Akihiro Tomita, Junji Hiraga, Hitoshi Kiyoi, Tomohiro Kinoshita, Tomoki Naoe

Blood (2007) 110 (11): 3423.

https://doi.org/10.1182/blood.V110.11.3423.3423

Published: 2007

Journal Articles

Restoration of Rituximab Sensitivity in CD20 Negative B-Cell Lymphoma Cells; Epigenetic Change of CD20 Expression after Treatment of Rituximab.

Akihiro Tomita, Junji Hiraga, Hitoshi Kiyoi, Tomohiro Kinoshita, Tomoki Naoe

Blood (2006) 108 (11): 4307.

https://doi.org/10.1182/blood.V108.11.4307.4307

Published: 2006

Journal Articles

Prognostic Analysis of Aberrant Somatic Hypermutation of RhoH in Diffuse Large B Cell Lymphoma.

Akira Katsumi, MD, PhD, Junji Hiraga, M.D., Ph.D., Toshihiro Iwasaki, M.D., Akihiro Abe, M.D., Ph.D., Hitoshi Kiyoi, M.D., Ph.D., Tadashi Matsushita, M.D., Ph.D., Tomohiro Kinoshita, M.D., Ph.D., Tomoki Naoe, M.D., Ph.D.

Blood (2006) 108 (11): 2041.

https://doi.org/10.1182/blood.V108.11.2041.2041

Published: 2006

NARROW

Survival and CNS Relapse in Patients with CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study in Japan

Prospective Study of the Usefulness of Liquid Biopsy in Patients with Unknown Fever Suspected of Malignant Lymphoma

CD20 Protein Immunohistochemistry-Positive/Flow Cytometry-Negative Diffuse Large B-Cell Lymphoma—Analyses of the Molecular Mechanisms and Rituximab Effectiveness

Clinical Significance of Genetic Mutations of CD79B , CARD11 , MYD88 , and EZH2 Genes in Diffuse Large B-Cell Lymphoma Patients

Retention of Slow-Cycling CD34 + cells During Imatinib Treatment and Rapid Decline After 2nd ABL-TKI Treatment in Ph + Leukemia Cells

CD20-Negative Phenotypic Change In B-Cell Lymphoma Cells After Using Rituximab: Possibility of a Particular Clinicopathologic Phenomenon Post-Rituximab Extranodal CD20-Negative Lymphoma

Rapid Reduction of Chronic Myeloid Leukemia Stem Cells After Treatment with Second-Generation BCR-ABL Kinase Inhibitors, Dasatinib and Nilotinib

Discrepancy of CD20 Protein Expression In IHC and FCM Analyses In Primary B-Cell Lymphoma: Relationship Between FCM-Negative Phenotype and Rituximab Binding with Lymphoma Cells

MS4A1 (CD20) Gene Expression Is Down-Regulated by Recruiting the Histone Deacetylase Protein Complex to the Promoter in the CD20-Negative B-Lymphoma Cells After Treatment with Rituximab.

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance

Relationship Between Post-Translational Modification of CD20 Protein and the Responsiveness to Rituximab Treatment

Epigenetic Regulation of CD20 Protein Expression in B-Cell Lymphoma Cells after Rituximab-Containing Chemotherapy.

Restoration of Rituximab Sensitivity in CD20 Negative B-Cell Lymphoma Cells; Epigenetic Change of CD20 Expression after Treatment of Rituximab.

Prognostic Analysis of Aberrant Somatic Hypermutation of RhoH in Diffuse Large B Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only